PharmTech
CONTINUE TO SITE

OR WAIT null SECS

Pharmaceutical Technology
Spotlight
COVID-19 UpdateAnalyticsDrug DevelopmentManufacturingOutsourcingQuality Systems2020 Bio/Pharma Virtual Congress
Topic
View MoreAnalytical Method DevelopmentAPIsAseptic ProcessingBiologic DrugsDosage FormsDrug DeliveryEquipmentExcipientsFormulationPackagingProcess Control/PATProcess DevelopmentQA/QCRegulatory ActionSupply Chain
News
All NewsTop NewsIndustry NewsBio/Pharma NewsSupplier NewsNews from EuropeEvents
Publications
All PublicationsPharmTechPharmTech Europe
Resources
Front & CenterPharma InsightsSponsored eBooksSponsored PodcastsSponsored VideosWhitepapers
WebcastsMarketplace
Subscribe
EnewslettersMagazine North AmericaMagazine Europe

  • About Us
  • Advertise
  • Contact Us
  • Editorial Info
  • Editorial Contacts
  • Editorial Advisory Board
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
  • MJHLS Brand Logo

© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.

Spotlight
  • COVID-19 Update
  • Analytics
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
  • 2020 Bio/Pharma Virtual Congress
TopicSee All >
  • Analytical Method Development
  • APIs
  • Aseptic Processing
  • Biologic Drugs
  • Dosage Forms
  • Drug Delivery
  • Equipment
  • Excipients
  • Formulation
  • Packaging
  • Process Control/PAT
  • Process Development
  • QA/QC
  • Regulatory Action
  • Supply Chain
  • About Us
  • Advertise
  • Contact Us
  • Editorial Info
  • Editorial Contacts
  • Editorial Advisory Board
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.

Nanofactories: The next frontier in protein synthesis?

April 15, 2012
Patricia Van Arnum
Patricia Van Arnum

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Researchers at the Massachusetts Institute of Technology (MIT) recently developed nanoparticles that can be controllably triggered to synthesize proteins.

Researchers at the Massachusetts Institute of Technology (MIT) recently developed nanoparticles that can be controllably triggered to synthesize proteins. The hope is that particles could be used to deliver small proteins that kill cancer cells and eventually larger proteins such as antibodies that trigger the immune system to destroy tumors.

The nanoparticles consist of lipid vesicles filled with the cellular machinery responsible for transcription and translation, including amino acids, ribosomes, and DNA caged with a photo-labile protecting group. These particles served as nanofactories capable of producing proteins including green fluorescent protein (GFP) and enzymatically active luciferase. In vitro and in vivo protein synthesis was spatially and temporally controllable and could be initiated by irradiating micron-scale regions on the timescale of milliseconds. (1).

The researchers designed the new nanoparticles to self-assemble from a mixture that includes lipids, which form the particles’ outer shells, plus a mixture of ribosomes, amino acids, and the enzymes needed for protein synthesis. Also included in the mixture are DNA sequences for the desired proteins. The DNA is trapped by DMNPE, which reversibly binds to it. This compound releases the DNA when exposed to ultraviolet light. In this study, particles were programmed to produce either GFP or luciferase. Tests in mice showed that the particles were successfully prompted to produce protein when UV light shone on them, according to an Apr. 9, 2012, MIT press release.

Although more testing must be done to show that the nanoparticles can reach their intended destination in humans and that they can be used to produce therapeutic proteins, the research is an interesting start. The researchers are working on particles that can synthesize potential cancer drugs by targeting protein production that could be turned on only in the tumor, thereby avoiding side effects in healthy cells. The team also is working on new ways to activate the nanoparticles. Possible approaches include production triggered by acidity level or other biological conditions specific to certain body regions or cells, according to the MIT release.

Reference
1. A. Schroeder et al, ” Remotely Activated Protein-Producing Nanoparticles,” Nano Lett., online, DOI: 10.1021/nl2036047, Mar. 20, 2012.

Related Content:

PharmTech Talk
FDA Documents Achievements and Plans for Future
COVID-19 Vaccine Makers Overcome Challenges to Ramp Up Production
FDA Blasts Misleading Opioid Promotion